IP Library Granted Patent US 11,382,875
Granted Patent B2
US 11,382,875 · App. 16/498,898 · Granted Jul 12, 2022

Methods and compositions for modulating β-amyloid/α7-nAChR interactions

Inventors: Aaron McMurtray (Torrance, CA); Julia Chung (Torrance, CA); Natalie Diaz (Torrance, CA); Sean Ekins (Raleigh, NC)
Assignees: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Collaborations Pharmaceuticals, Inc.
A61K31/138A61K45/06A61P25/16A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,382,875
App. No.
16/498,898
Granted
Jul 12, 2022
Kind
B2
Abstract

Methods of modulating the interaction between β-amyloid and α7-nAChR are provided. Aspects of the methods include administering to the subject an effective amount of a naphthalene derivative active agent. Compositions and kits for practicing the subject methods are also provided. The methods, compositions and kits find use in treating a variety of applications, such as treating a subject for a neurodegenerative disease, e.g., Alzheimer's disease.

Claims (15)

1. A method of treating a subject for a neurodegenerative disease, the method comprising:

administering to the subject an effective amount of a compound selected from the group consisting of:

to treat the subject for the neurodegenerative disease.

2. The method according to claim 1 , wherein the neurodegenerative disease is selected from the group consisting of: Alzheimer's disease, Parkinson's disease, frontotemporal dementia, progressive supranuclear palsy, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, multiple sclerosis, multi-system atrophy, glaucoma, ataxias, myotonic dystrophy and dementia.

3. The method according to claim 2 , wherein the neurodegenerative disease is Alzheimer's disease.

4. The method according to claim 1 , wherein the subject is a mammal.

5. The method according to claim 4 , wherein the subject is a human.

6. A pharmaceutical composition comprising:

a) a compound selected from the group consisting of:

and

b) a pharmaceutical delivery vehicle.

7. A kit comprising:

a dose of a compound selected from the group consisting of:

and

a dose of a second active agent having neurodegenerative disease therapeutic activity.

Assignments (3)
CHANGE OF NAME Recorded Jan 30, 2020
From: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
To: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
Reel/Frame 051758/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2019
From: MCMURTRAY, AARON; CHUNG, JULIA; DIAZ, NATALIE
To: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
Reel/Frame 050566/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2019
From: EKINS, SEAN
To: COLLABORATIONS PHARMACEUTICALS, INC.
Reel/Frame 050566/0900 →
Continuity (2)
Provisional Application 62482867 · Apr 7, 2017
Related Publication 20210093587A1 · Apr 1, 2021